Evidence-based dentistry · 2010
Drug treatment for oral submucous fibrosis.
КомментарийСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Angadi Punnya V
Аннотация
DATA SOURCES: Searches were made for relevant data using Medline and the International Poster Journal of Dentistry and Oral Medicine online database (see ipj.quintessenz.de).
STUDY SELECTION: Meta-analyses, randomised controlled trials (RCT), clinical trials and other experimental designs were considered.
DATA EXTRACTION AND SYNTHESIS: Because of heterogeneity of study designs and drugs used, a qualitative synthesis was conducted.
RESULTS: Seventeen publications were identified of which 15 were included. Of these, six were RCT, four were clinical trials/ controlled clinical trials, and five were other types experimental studies. The studies in total involved 1224 patients. The rate of those lost to followup reached 30% in some studies. The drugs used to treat oral submucous fibrosis (OSF) were categorised into steroids, enzymes, cardiovascular drugs, antioxidants, vitamins and microelements.
CONCLUSIONS: There are few high-quality studies available and the present drug treatments are in general empirical and treat only symptoms. There is a need for high-quality RCT in this area, especially studies involving combined and sequential therapy.
STUDY SELECTION: Meta-analyses, randomised controlled trials (RCT), clinical trials and other experimental designs were considered.
DATA EXTRACTION AND SYNTHESIS: Because of heterogeneity of study designs and drugs used, a qualitative synthesis was conducted.
RESULTS: Seventeen publications were identified of which 15 were included. Of these, six were RCT, four were clinical trials/ controlled clinical trials, and five were other types experimental studies. The studies in total involved 1224 patients. The rate of those lost to followup reached 30% in some studies. The drugs used to treat oral submucous fibrosis (OSF) were categorised into steroids, enzymes, cardiovascular drugs, antioxidants, vitamins and microelements.
CONCLUSIONS: There are few high-quality studies available and the present drug treatments are in general empirical and treat only symptoms. There is a need for high-quality RCT in this area, especially studies involving combined and sequential therapy.